FunPep
Japanese biotech developing functional peptides for skin ulcers and antibody-inducing vaccines, with a Phase III candidate showing angiogenesis and antimicrobial activity.
Private Company
Funding information not available
AI Company Overview
Japanese biotech developing functional peptides for skin ulcers and antibody-inducing vaccines, with a Phase III candidate showing angiogenesis and antimicrobial activity.
Technology Platform
Functional peptide design and synthesis platform creating modified peptides with enhanced stability and specific biological activities, including antibody-inducing peptides that stimulate B-cell immune responses.
Opportunities
Risk Factors
Competitive Landscape
Competes with other peptide therapeutic companies and traditional wound care products; differentiation through multifunctional peptides with combined angiogenic/antimicrobial activity and innovative antibody-inducing approach.